| Literature DB >> 27472308 |
Angela M Chapa-Oliver1, Laura Mejía-Teniente2.
Abstract
Capsaicinoids are plant secondary metabolites, capsaicin being the principal responsible for the pungency of chili peppers. It is biosynthesized through two pathways involved in phenylpropanoid and fatty acid metabolism. Plant capsaicin concentration is mainly affected by genetic, environmental and crop management factors. However, its synthesis can be enhanced by the use of elicitors. Capsaicin is employed as food additive and in pharmaceutical applications. Additionally, it has been found that capsaicin can act as a cancer preventive agent and shows wide applications against various types of cancer. This review is an approach in contextualizing the use of controlled stress on the plant to increase the content of capsaicin, highlighting its synthesis and its potential use as anticancer agent.Entities:
Keywords: apoptosis; cancer; capsaicin; cell death; elicitors; stress
Mesh:
Substances:
Year: 2016 PMID: 27472308 PMCID: PMC6274000 DOI: 10.3390/molecules21080931
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of capsaicin [7].
Figure 2Capsaicin biosynthetic pathway modified from Arora et al. [11]. Enzymes involved in the biosynthetic pathway: PAL, phenylalanine ammonia lyase; C4H, cinnamic acid 4-hydroxylase; Ca3H, coumaric acid 3-hydroxylase; COMT, caffeic acid O-methyltransferase; pAMT, putative aminotransferase; BCAT, branchedchain amino acid transferase; FAS fatty acid synthase complex, KAS, β-ketoacyl-[acyl-carrier-protein] (ACP) synthase; ACL, acyl carrier protein; FATA, acyl-ACP thioesterase; Desnaturase; ACS, acyl-CoA synthase; CS, capsaicin synthase.
Studies evaluating the capsaicin effect on cancerous cells.
| Cancer Type | Cell Line | Effective Doses (μM) | Anticancer Mechanism | Ref. |
|---|---|---|---|---|
| Human colorectal cancer | HCT 116 | 100–200 | Induced Autophagy | [ |
| LoVo | 100 | Induced anti-tumorigenesis. Deregulation of β-catenin/TCF-dependent signaling | [ | |
| SW480 | [ | |||
| Colo 205 | 150 | Induced cell death, increased ROS and pro-apoptotic proteins | [ | |
| Human breast cancer | MCF-7 | 50–300 | Induced Autophagy. Inhibited growth and induced apoptosis | [ |
| T47D | 200 | Inhibited growth, increased apoptosis | [ | |
| BT-474 | ||||
| SKBR-3 | ||||
| MDA-MB231 | 20–200 | Induced apoptosis and dysfunctions in mitochondria. Antiproliferative activity and arrest of cell cycle into G2/M phase. Enhances the apoptotic effects of TRIAL by activating the calcium-CaMKII-Sp1 pathway | ||
| Human prostate cancer | LNCaP | 40–50 | Inhibited proliferation. Induced apoptosis | [ |
| PC-3 | 20–50 | |||
| DU-145 | 500 | |||
| RWPE-1 | 40 | |||
| Human myeloid Leukemia | HL-60 | >50 | Induced G0/G1 phase cell cycle arrest and apoptosis | [ |
| U937 | 200 | Enhances the apoptotic effects of TRIAL by activating the calcium-CaMKII-Sp1 pathway | [ | |
| THP-1 | ||||
| Human esophageal epidermoid carcinoma | CE 81T/VGH | 100 | Induced apoptosis and G0/G1 phase cell cycle arrest | [ |
| Human melanoma | A375 | 100 | Inhibited cell growth and promoted apoptosis | [ |
| Human KB cancer cells | KB cells | 150–250 | Reduced cell proliferation and viability. Induced cell death and cell cycle arrest in G2/M phase | [ |
| Mouse melanoma | B16-F10 | 50 | Inhibited cell migration. Induced apoptosis | [ |
| Human Pancreatic cancer | AsPC-1 | 150 | Inhibited proliferation. Induced apoptosis and generated ROS | [ |
| BxPC-3 | ||||
| PANC-1 | 200 | Induced G0/G1 phase cell cycle arrest and apoptosis. | [ | |
| Human multiple myeloma | U266 | >5 | Inhibited cell proliferation, caused accumulation of cells in G1 phase | [ |
| MM.1S | ||||
| Human hepatoma | HepG2 | 10–200 | Decreased cell viability, generated ROS and activated caspase-3. Induced apoptosis and autophagy | [ |
| Hep3B | 200 | Enhances the apoptotic effects of TRIAL by activating the calcium-CaMKII-Sp1 pathway | [ | |
| Human nasopharyngeal carcinoma | NPC-TW 039 | 200–400 | Induced G0/G1 phase arrest and apoptosis. Increased ROS and activated caspases. Increased cytosolic Ca2+ | [ |
| Human gastric carcinoma | SMC-1 | 200 | Induced apoptosis | [ |
| Human bladder cancer | T24 | 100 | Induced ROS production and mitochondrial membrane depolarization | [ |
| Human small cell lung cancer | NCI-H69 | 50 | Suppressed growth in all four cell lines | [ |
| NCI-H82 | ||||
| DMS53 | ||||
| DMS114 |
Figure 3Summary of some of the pro-apoptotic mechanisms and anti-cancer activity of capsaicin in some cancerous cells [17,52,62,72,73,74].
Studies evaluating capsaicin anticancer effect in vivo.
| Animal Model | Capsaicin Doses | Treatment | Results | Ref. |
|---|---|---|---|---|
| BALB/cJ and BALB/cJ nu/un mice injected with live tumor cells CT26 | 100–200 μg | Intratumoral on Days 5, 10 and 15 | Retarded progression of injected tumors | [ |
| BNX nu/un male mice mice injected with PC-3 cells | 5 mg/kg/day | Gavage 3 days per week for 4 weeks | Reduced tumor growth | [ |
| Athymic nude mice injected with PC-3 cells | 5 mg/kg body weight | Subcutaneous injection every two days for 14 days | Suppressed PC-3 tumor growth and induced apoptosis | [ |
| Female athymic nude mice injected subcutaneously with AsPC-1 tumor cells | 2.5 mg/kg body weight | Five times a week | Suppressed growth of tumor xenografts without adverse effects | [ |
| 5 mg/kg body weight | Three times a week | [ | ||
| Male athymic nu/nu mice injected with U266 cells | 1 mg/kg | Twice a week for 3 weeks | Inhibited growth of U266 xenograft tumors | [ |
| Male Athymic nude mice injected subcutaneously with T24 cells | 5 mg/kg | Subcutaneous injection every 3 days for 4 weeks | Slowed growth of xenograph tumors | [ |
| Female triple deficient beige/nude/xid mice (BNX) injected with MDA-MB231 cells | 5 mg/kg | Oral gavage 3 days per week for 4 weeks | Decrease the size of tumors by 50% | [ |
| Male nude mice injected subcutaneously with H69 cells | 10 mg/kg body weight | Solid diet until tumors of the control group reached 2000 mm3 | Tumor growth suppression | [ |
| Female BALB/c athymic nude mice injected subcutaneously with Colo 205 cells | 1 mg/kg | Intraperitoneal injected. Four weeks of treatment | Inhibition of tumor growth | [ |
| 3 mg/kg | ||||
| Female athymic nude mice injected subcutaneously with AsPC-1 tumor cells | 2.5 mg/kg | Orally fed 5 days a week for 6 weeks | Reduced tumor SOD activity by 60% and increased the ratio of oxidized glutathione to glutathione | [ |
| Male BALB/c (nu/nu) athymic nude mice injected subcutaneously with PANC-1 cells | 5 mg/kg body weight | Gavage 3 days per week for 4 weeks | Inhibited the growth of pancreatic cancer PANC-1 cell xenografts. | [ |